A profound Understanding of Biopharmaceuticals
The experience of Boehringer Ingelheim comes from a century of pioneering achievement. First in industrial biotechnology, then in the commercial application of recombinant DNA techniques. We command profound understanding of this exciting and fast-moving field.
Among the world's top biopharmaceutical companies
All of the elements required for outsourcing biopharmaceutical development and manufacture, from high expression system to fill & finish, and patient convenient application systems can be found within the corporate capabilities of Boehringer Ingelheim in a so called one-stop shop.
At our large-scale production sites in Vienna, Austria and Biberach, Germany we have extablished a strong track record in regulatory approval since more than 25 years. So far 14 DNA-derived biopharmaceutical products have been successfully introduced to the market.
A well-filled R&D pipeline
One of our major efforts is the development of new biological entities (NBEs) for the treatment of diseases in the areas of:
- Respiratory
- Cardiovascular
- Virology
- Neurology (CNS)
- Immunology
- Metabolism
- Oncology
All R & D activities in these therapeutic areas are supported by in-licensing for early and late stage pharmaceutical and biopharmaceutical products.
